<DOC>
	<DOC>NCT00725010</DOC>
	<brief_summary>The purpose of this program is to evaluate the safety, tolerability, and efficacy of the new concomitant and sequential temozolomide regimen in newly diagnosed Glioblastoma patients in a routine care setting.</brief_summary>
	<brief_title>Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816)</brief_title>
	<detailed_description>Participant sampling method: consecutive patient sampling.</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Newly diagnosed Glioblastoma multiforme History of hypersensitivity to temozolomide or its components, or to dacarbazine. Women who are pregnant or breastfeeding. Patients with severe myelosuppression.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>